FDA raised conflict of interest concerns ahead of new peptide panel

FDA Advisory Committee to Address Compounding of Peptides Amid Market Surge

An FDA advisory committee is scheduled to meet on July 23rd and 24th in White Oak, Maryland, to determine whether a specific group of peptides should be legally permitted for production by compounding pharmacies. This regulatory review comes as the use of various peptides—such as BPC-157, TB-500, and MOTS-c—has expanded from fringe communities of biohackers and athletes into broader professional and leadership circles. The market for these substances is substantial, with industry investors estimating the current black market for peptides at between $1 billion and $3 billion.

The Science and Risks of Unapproved Peptides

Peptides are microproteins consisting of strings of amino acids, which the body naturally produces to regulate biological systems. While certain synthetic peptides, such as insulin and GLP-1 receptor agonists, have gained FDA approval and are widely used in medicine, many of the substances currently trending online have not undergone rigorous clinical testing. Physician and researcher Dhruv Khullar, an associate professor at Weill Cornell Medical College, notes that while some of these peptides may show theoretical promise or effects in mouse models, they lack the formal approval and safety verification associated with standard pharmaceutical drugs. Despite this, these substances are being marketed online and through social media with claims of enhancing strength, energy, endurance, recovery, and other physiological benefits. According to experts, individuals are increasingly sourcing these products from labs globally or through medical providers promoting off-label usage.

Drivers of the Peptide Boom in Leadership

The rise in peptide interest is closely linked to the broader cultural impact of GLP-1 medications, which have influenced consumer behavior and corporate strategies, including menu shifts in the food industry. For business leaders, the appeal of peptides is often framed through the lenses of “agency” and “leverage.” In an environment characterized by volatile factors such as AI disruption, inflation, and geopolitical instability, leaders face significant challenges in maintaining control over their professional outcomes. Consequently, many are turning to their own biology as a domain where they can exert direct influence. This pursuit of personal optimization reflects a broader shift toward seeking alternative health solutions, sometimes accompanied by a sense of institutional distrust similar to the rise of decentralized financial systems.

Seeking a Competitive Edge

Beyond the desire for agency, leaders are increasingly viewing their physical capacity as a metric for professional leverage. In hyper-competitive business hubs like Silicon Valley, New York, and London, the pursuit of one-percent advantages—ranging from cold plunges and DEXA scans to peptide regimens—has become a strategy for maintaining performance. Telehealth platforms have capitalized on this trend, treating peptides as part of a longevity strategy similar to the demand for GLP-1s. Analysts from Leerink Partners have identified a market opportunity of approximately $2.2 billion for telehealth platforms within this space. As the FDA prepares its upcoming review, the future of the market remains in flux, with potential shifts expected as regulators, clinicians, and companies continue to reshape the availability and oversight of these substances.